Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
3,387 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00028535 | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00030368 | Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00042874 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 77 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00045526 | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00047047 | Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00047190 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00047307 | Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00049192 | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00055757 | Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00055861 | Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00062244 | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00063947 | Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00064324 | Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00066768 | Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00070551 | GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00079131 | Oblimersen in Treating Patients With Merkel Cell Carcinoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00087074 | CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00093821 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00098488 | 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00098501 | CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | terminated | Phase 1 | 88 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00109824 | Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00119236 | 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00397787 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00002587 | Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00003992 | Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 | completed | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 2 | Jun 3, 2013 | clinicaltrials |
| NCT00005976 | Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Jun 3, 2013 | clinicaltrials |
| NCT00006001 | SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer | terminated | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00006014 | SU5416 in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00006222 | EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00062387 | Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00091130 | SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells | completed | Phase 2 | 139 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00513604 | Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | completed | Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00002556 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | completed | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 1 | May 31, 2013 | clinicaltrials |
| NCT00009958 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer | terminated | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00054548 | Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00079014 | 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00084877 | Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00001586 | Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | May 15, 2013 | clinicaltrials |
| NCT00095667 | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | May 8, 2013 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials